戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  odds ratio >1 favoring the groups receiving experimental therapy).
2  patients received standard and 320 received experimental therapy.
3 erapy (TDF + pegIFN) followed by 48 weeks of experimental therapy.
4  390 participants who had been randomized to experimental therapy.
5 ons according to authors' endorsement of the experimental therapy.
6 C, although there was no sign of bias toward experimental therapy.
7 y in five fractions to further evaluate this experimental therapy.
8 ond which it makes sense to give the patient experimental therapy.
9 ility to clinical trials with novel targeted experimental therapies.
10 o differential access to clinical trials and experimental therapies.
11 tments of standard adjuvant chemotherapy and experimental therapies.
12 common control arm while evaluating multiple experimental therapies.
13 atment response in animal models of PD after experimental therapies.
14  for pharmacological TRPC6 modulation within experimental therapies.
15 is provides a guide for future assessment of experimental therapies.
16 resulted in full recovery without the use of experimental therapies.
17 s of MN and evaluating the efficacy of novel experimental therapies.
18  with mutations should be selected for novel experimental therapies.
19 udies of patients, often in conjunction with experimental therapies.
20 ocesses, and new opportunities for exploring experimental therapies.
21  with advanced disease may be candidates for experimental therapies.
22  control of JAB1 could be a novel target for experimental therapies.
23  mechanisms, and in assessing the effects of experimental therapies.
24 tional section of this review will deal with experimental therapies.
25 to define the disease course and response to experimental therapies.
26 7.9%]) who received anti-EGFR rechallenge as experimental therapy (48 received cetuximab plus aveluma
27 s of eBEACOPP; ie, eight cycles in total) or experimental therapy (an additional six cycles of eBEACO
28 ssigned (1:1) to receive standard therapy or experimental therapy (an additional two cycles of eBEACO
29 k control measures and the administration of experimental therapies and a vaccine have been initiated
30 mulations of hypothetical multiarm trials of experimental therapies and associated biomarkers of vary
31 that can be tailored for rapid assessment of experimental therapies and delivery of precision medicin
32 ized neoadjuvant platform trial that screens experimental therapies and efficiently identifies potent
33 latforms offer the ability to validate human experimental therapies and may foster their rapid transl
34 erbs may confound the results of standard or experimental therapies and may produce clinically signif
35 identifying epidemiological risk factors and experimental therapies and vaccines.
36 e high expectations regarding the success of experimental therapy and discount potential toxicity.
37 L may affect the expectation of benefit from experimental therapy and, ultimately, treatment choice.
38 ct therapy appropriately toward cure, use of experimental therapies, and/or palliation.
39 re used widely to investigate tumor biology, experimental therapy, and biomarkers.
40 atment is currently symptomatic, but several experimental therapies are in development.
41 een relatively refractory to virtually every experimental therapy attempted.
42  for unruptured brain AVMs may be considered experimental therapy awaiting the results from 'A Random
43 nical trials where patients are matched with experimental therapies based on their genomic profile ra
44                                 We evaluated experimental therapies being tested in clinical trials i
45 ial for toxicity (29.8% v 45.6%, P =.01) for experimental therapy, compared with standard therapy.
46 all survival (OS) rate at 6 months, with the experimental therapy considered insufficiently active wi
47  long-term effectiveness and side effects of experimental therapies delivered to adult mice, we devel
48                                  None of the experimental therapies demonstrated a significant OS ben
49                                              Experimental therapy evaluated the survival of mice bear
50                                      From an experimental therapy first used clinically in 2012, a de
51                                              Experimental therapies for Alzheimer's disease (AD) are
52 promise for minimally invasive assessment of experimental therapies for DMD and other neuromuscular d
53                        With the emergence of experimental therapies for Duchenne muscular dystrophy (
54  that can be used to monitor the efficacy of experimental therapies for Duchenne Muscular Dystrophy (
55 increase in response to standard-of-care and experimental therapies for multiple breast cancer subtyp
56 hysiological assays in early-phase trials of experimental therapies for PD and other neurodegenerativ
57 hat NOD mice have been used to test numerous experimental therapies for SS, caution needs to be exert
58 his study reviews the newest developments on experimental therapies for the treatment of food allergy
59 ouse model should prove valuable for testing experimental therapies for this devastating disorder and
60 ld be considered in designing and monitoring experimental therapies for this disease.
61 e pathogenesis of BPD as well as current and experimental therapies for treatment of BPD.
62          Recently, IL-12 has been used as an experimental therapy for cancer.
63 ogeneic islet transplantation is a promising experimental therapy for poorly controlled diabetes.
64 olaparib plus temozolomide (OT), a promising experimental therapy for relapsed SCLC.
65     Intrahepatic islet transplantation is an experimental therapy for type 1 diabetes.
66             Hence, it is a promising, albeit experimental, therapy for Parkinson's disease (PD).
67  therapy compared with 28% (11 of 39) in the experimental therapy group (p = 0.0001).
68 p but in 0% (0 of 25) of the patients in the experimental therapy group (p = 0.0001).
69 o significantly better among patients in the experimental-therapy group (72+/-3.4 percent vs. 61+/-3.
70 -free survival among the 198 patients in the experimental-therapy group was 69+/-3 percent, as compar
71  to the standard-therapy group and 58 to the experimental-therapy group.
72                                   While many experimental therapies have shown great promise in treat
73 potential benefits of surgical procedures or experimental therapy have to be weighed against the chan
74 onse to transfusion, and the optimization of experimental therapies in development.
75 ical function, and offer a model for testing experimental therapies in this and similar disorders.
76 ing quantitative measures of the efficacy of experimental therapies in this rodent model of Parkinson
77 n or function may provide a novel target for experimental therapy in patients with ALCL.
78 t obstacles to the successful translation of experimental therapies, in large part due to the absence
79 aptively randomly assigned to one of several experimental therapies, including MK-2206, or control.
80                     The translation of these experimental therapies into clinical benefit is a welcom
81                 In addition, a wide range of experimental therapies is routinely provided in an attem
82 -specified ancillary study assessing whether experimental therapy is noninferior, and if met, superio
83 mated potential benefits and toxicities from experimental therapy (mean expected benefit, 59.8% v 23.
84 otential of repurposing of this drug for the experimental therapy of diabetic cardiovascular complica
85                                              Experimental therapy of mice bearing peritoneal MKN-45P
86 chanism-based neuromodulating devices in the experimental therapy of RA and possibly other autoimmune
87 rs have entered clinical development for the experimental therapy of various cardiovascular and other
88 5 pathway offers novel opportunities for the experimental therapy of various forms of shock, sepsis,
89 or discrimination of the relative effects of experimental therapies on new inflammatory activity from
90 missing receptor information, neoadjuvant or experimental therapy, or who were diagnosed with breast
91 956-2016) were identified for which the new, experimental therapy provided a statistically significan
92 patient perception of potential benefit from experimental therapy (r =.48, P =.01).
93 clinical trials, which often involve complex experimental therapy regimens and perhaps analytic treat
94 rant cell-signaling pathways, as well as new experimental therapies such as immunotherapy.
95 and may enable precise assessment of whether experimental therapies, such as gene therapy, provide a
96        We critically assess the potential of experimental therapies targeting alpha-synuclein, and di
97                                              Experimental therapies targeting Bcl-2 family mRNAs or p
98                                              Experimental therapies targeting Bcl-2-family mRNAs or p
99                                      Several experimental therapies targeting T-cells are in clinical
100 assigned to groups that received 48 weeks of experimental therapy (TDF + pegIFN + REP 2139-Mg or REP
101                                              Experimental therapies that are undergoing evaluation in
102 ctors could "prime" the neuron to respond to experimental therapies that promote axonal plasticity or
103 gh-risk disease who should be considered for experimental therapy that might improve outcome.
104 patients into two groups, one to receive the experimental therapy, the other serving as the control.
105 h immune-mediated neuropathies; and (ii) new/experimental therapies to prevent anti-ganglioside antib
106 re directed towards the development of novel experimental therapies to target these molecular and bio
107 ndomized clinical trial of LTBI in which the experimental therapy was 50% efficacious and the control
108 d therapy was weekly cisplatin 40 mg/m2, and experimental therapy was PVI FU 225 mg/m2/d for 5 d/wk f
109 r to improve the safety and efficacy of this experimental therapy, we need a better understanding of
110                              These and other experimental therapies will be discussed critically.
111          We tested the antitumor activity of experimental therapy with 2 distinct antiangiogenic drug
112 ed chemotherapy (regimen A) for 17 cycles or experimental therapy with five cycles of VTC within the
113                      Ribavirin is used as an experimental therapy with other viruses.
114                         The patient received experimental therapy with quinacrine, but deteriorated a
115 to demonstrate the feasibility of monitoring experimental therapy with siRNA in vivo, targeted knockd
116                               Interestingly, experimental therapy with tenascin-C (TNC-C) and neuropi
117 stine, cyclophosphamide, and dactinomycin or experimental therapy with these four drugs alternating w
118 atment outcomes (eg, median 60% benefit from experimental therapy), with those choosing to participat
119 derable progress has been made in developing experimental therapies, with adeno-associated virus (AAV

 
Page Top